Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Indication: Asciminib for CML
Study: Phase 1, dose-escalation study Refractory CML pts with prior at least two ATP-competitive TKIs Asciminib once or twice daily (10 to 200 mg) Efficacy: 34 (92%) with a hematologic